InflaRx Izicopan Study Reports No Serious Adverse Events Across 86 Healthy Participants
Previously announced results are now peer-reviewed, supporting the company's plans to develop the oral drug for inflammatory diseases.
InflaRx, which develops drugs that block inflammation linked to the immune protein C5a or its receptor, said an izicopan study in 86 healthy participants reported no serious adverse events. The company said in a statement Friday that Clinical Pharmacology in Drug Development had published the previously announced early-stage results, which management sees as support for further clinical development.
Rapid Blockade, Repeated Dosing
The study tested izicopan, an oral drug formerly called INF904, against a placebo at a single research center. Safety was the main goal; researchers also examined how the body processed the drug and how effectively it blocked its target. Of the participants, 66 received izicopan and 20 received placebo, with everyone included in the safety assessment.
Blood samples showed more than 90% blockade of a C5a-triggered cellular response generally within two to four hours of single doses of at least 10 mg. Strong activity persisted at 24 hours in most dose groups. With twice-daily doses of 30 mg or 90 mg, blockade surpassed 95% at several measurements from Day 2 through Day 15.
Single doses ranged from 3 mg to 240 mg. Repeated treatment lasted 14 days, using 30 mg once daily, 30 mg twice daily or 90 mg twice daily. Adverse events were mild or moderate, and researchers observed no dose-related safety pattern or clinically relevant changes in laboratory tests, vital signs, heart monitoring or physical examinations.
Peak blood concentrations occurred approximately 3.5 to 6 hours after dosing. Exposure generally rose in proportion to the dose in the single-dose portion.
From Healthy Volunteers To Patient Programs
Niels Riedemann, chief executive officer and founder of InflaRx, said: “Together, these findings provide a solid clinical pharmacology foundation for our Phase 2 programs and reinforce the potential of izicopan as an oral therapy for patients with serious immune-inflammatory diseases driven by excessive C5a signaling.”
InflaRx plans to develop izicopan for ANCA-associated vasculitis and additional kidney indications. Its mid-stage skin-disease study also reported no safety concerns. In hidradenitis suppurativa, the company reported reductions in abscesses, nodules, draining tunnels and patient-reported pain over four weeks of treatment; clinical responses continued to deepen four weeks after treatment ended. In chronic spontaneous urticaria, it reported improved disease control and lower activity scores, particularly among patients with severe disease.
Laboratory experiments also found that izicopan did not show time-dependent inhibition of CYP3A4/5, an enzyme involved in processing drugs including glucocorticoids. That finding came from laboratory testing, distinct from the healthy-volunteer trial.
The Jena, Germany-based company's portfolio includes vilobelimab, an intravenous antibody sold in the United States as GOHIBIC for critically ill COVID-19 patients. Vilobelimab received European Commission marketing authorization in January 2025. InflaRx also has IFX002 in preclinical development.
Friday's announcement adds peer-reviewed publication to results already made public; the company's planned kidney-disease development remains the next clinical application it is pursuing.
Sources
- Form 6-K — Findings support Phase 2 development of izicopan in immune-inflammatory diseases — SEC EDGAR
- InflaRx N.V. Form 6-K filed November 3, 2026 — sec.gov
- InflaRx N.V. (IFRX) Analyst/Investor Day Transcript | Seeking Alpha — seekingalpha.com
- InflaRx Announces Publication of Phase 1 Data Demonstrating — globenewswire.com